A220 ONTARIO POPULATION TRENDS IN INTESTINAL AND EXTRA-INTESTINAL CANCERS OVER 25 YEARS AMONG PERSONS WITH INFLAMMATORY BOWEL DISEASES AND MATCHED CONTROLS

NOT PUBLISHED AT AUTHOR’S REQUEST PLEASE ACKNOWLEDGE ALL FUNDING AGENCIES BY CHECKING THE APPLICABLE BOXES BELOW: CCC, CIHR DISCLOSURE OF INTEREST: S. Murthy: None Declared, G. Kaplan Grant / Research support from: Ferring, Janssen, AbbVie, GlaxoSmith Kline, Merck, and Shire, Consultant of: AbbVie, Janssen, Pfizer, Amgen, Takeda, Gilead, Speakers bureau of: AbbVie, Janssen, Pfizer, Amgen, and Takeda, S. Coward: None Declared, E. Kuenzig: None Declared, E. Benchimol Consultant of: Hoffman La-Roche Limited, Peabody & Arnold LLP, McKesson Canada, Dairy Farmers of Ontario for matters unrelated to medications used to treat inflammatory bowel disease., A. Zubieta: None Declared, A. Otley: None Declared, A. Bitton: None Declared, C. Bernstein Grant / Research support from: Abbvie Canada, Janssen Canada, Pfizer Canada, Bristol Myers Squibb Canada, Takeda Canada; Amgen Canada, Sandoz Canada , Consultant of: Abbvie Canada, Amgen Canada, Bristol Myers Squibb Canada, JAMP Pharmaceuticals, Janssen Canada, Pfizer Canada, Sandoz Canada, Takeda, Speakers bureau of: Abbvie Canada, Janssen Canada, Pfizer Canada and Takeda Canada, L. Targownik Grant / Research support from: Janssen Canada, Consultant of: AbbVie Canada, Takeda Canada, Merck Canada, Pfizer Canada, Janssen Canada, Roche Canada, and Sandoz Canada, J. Jones Consultant of: Janssen, Abbvie, Pfizer, Takeda, Speakers bureau of: Janssen, Abbvie, Pfizer, Takeda, J. Begum: None Declared, M. Pugliese: None Declared, H. Singh Consultant of: Pendopharm, Amgen Canada, Bristol Myers Squibb Canada, Roche Canada, Sandoz Canada, Takeda Canada, and Guardant Health, Inc.,